These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 38464532)

  • 41. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
    Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
    Front Immunol; 2022; 13():950079. PubMed ID: 36703982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
    Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
    Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic viruses as engineering platforms for combination immunotherapy.
    Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
    Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
    Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
    Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
    Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy.
    Floerchinger A; Engeland CE
    Methods Mol Biol; 2022; 2521():233-248. PubMed ID: 35733001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
    Wang S; Li Y; Xu C; Dong J; Wei J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation and Quantification of Cytotoxic Lymphocytes Following Oncolytic Virus Infection of Multi-cellular Tumor Spheroids.
    Jennings VA; Ilkow CS
    Methods Mol Biol; 2023; 2614():139-149. PubMed ID: 36587124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of oncolytic virus in tumor therapy.
    Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
    J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
    Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
    Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses.
    Bifulco M; Di Zazzo E; Napolitano F; Malfitano AM; Portella G
    Biochimie; 2023 Mar; 206():89-92. PubMed ID: 36273765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Updates to the antitumor mechanism of oncolytic virus.
    Bai Y; Hui P; Du X; Su X
    Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).
    Wang X; Zhong L; Zhao Y
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33760203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.